PMID- 36800677
OWN - NLM
STAT- MEDLINE
DCOM- 20230306
LR  - 20230324
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Print)
IS  - 1226-3303 (Linking)
VI  - 38
IP  - 2
DP  - 2023 Mar
TI  - Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line 
      treatment for extensive-stage small cell lung cancer.
PG  - 218-225
LID - 10.3904/kjim.2022.361 [doi]
AB  - BACKGROUND/AIMS: Despite the obvious benefits of adding immune checkpoint 
      inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage 
      small-cell lung cancer (ES-SCLC), real-world data remain scarce. METHODS: This 
      retrospective study included 89 patients with ES-SCLC treated with 
      platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in 
      combination with atezolizumab (atezolizumab group; n = 41) and compared the 
      survival outcomes between these two groups. RESULTS: Overall survival (OS) was 
      significantly longer in the atezolizumab group than in the chemo-only group (15.2 
      months vs. 8.5 months; p = 0.047), whereas the median progression-free survival 
      was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). 
      Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio 
      [HR], 0.223; 95% confidence interval [CI], 0.092-0.537; p = 0.001) and 
      atezolizumab administration (HR, 0.350; 95% CI, 0.184-0.668; p = 0.001) were 
      favorable prognostic factors for OS. In the thoracic radiation subgroup, patients 
      who received atezolizumab demonstrated favorable survival outcomes and no grade 
      3-4 adverse events (AEs). CONCLUSION: The addition of atezolizumab to 
      platinum-etoposide resulted in favorable outcomes in this real-world study. 
      Thoracic radiation was associated with improved OS and acceptable AE risk in 
      combination with immunotherapy in patients with ES-SCLC.
FAU - Kim, Soo Han
AU  - Kim SH
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
AD  - Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
FAU - Jo, Eun Jung
AU  - Jo EJ
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Mok, Jeongha
AU  - Mok J
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Lee, Kwangha
AU  - Lee K
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Kim, Ki Uk
AU  - Kim KU
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Park, Hye-Kyung
AU  - Park HK
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Lee, Min Ki
AU  - Lee MK
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Eom, Jung Seop
AU  - Eom JS
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
FAU - Kim, Mi-Hyun
AU  - Kim MH
AD  - Department of Internal Medicine, Pusan National University School of Medicine, 
      Busan, Korea.
AD  - Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230221
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - BG3F62OND5 (Carboplatin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Humans
MH  - *Small Cell Lung Carcinoma/drug therapy
MH  - Carboplatin/adverse effects
MH  - Etoposide/adverse effects
MH  - *Lung Neoplasms/drug therapy
MH  - Platinum/therapeutic use
MH  - Retrospective Studies
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC9993105
OTO - NOTNLM
OT  - Immunotherapy
OT  - Radiotherapy
OT  - Real-world evidence
OT  - Small cell lung carcinoma
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2023/02/21 06:00
MHDA- 2023/03/07 06:00
PMCR- 2023/03/01
CRDT- 2023/02/20 02:33
PHST- 2022/11/16 00:00 [received]
PHST- 2022/12/21 00:00 [accepted]
PHST- 2023/02/21 06:00 [pubmed]
PHST- 2023/03/07 06:00 [medline]
PHST- 2023/02/20 02:33 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - kjim.2022.361 [pii]
AID - kjim-2022-361 [pii]
AID - 10.3904/kjim.2022.361 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2023 Mar;38(2):218-225. doi: 10.3904/kjim.2022.361. Epub 
      2023 Feb 21.